肝硬化腹水住院患者中的β受体阻滞剂:死亡率及决定停药与重启的因素
该研究为NACSELD数据库的子分析,纳入7个中心716例肝硬化腹水住院患者,其中307例(43%)入院时使用β受体阻滞剂、366例(51%)为难治性腹水。β受体阻滞剂使用与入院时较低白细胞计数相关,未与更高死亡率相关;49%停药(因低平均动脉压、感染、急性肾损伤),40%出院前重启(主要因平均动脉压升高)。结论认为在低平均动脉压时停药、回升后重启的前提下,β受体阻滞剂在肝硬化腹水(含难治性腹水)患者中是安全的。
要点
- 肝硬化腹水住院患者使用β受体阻滞剂未与更高死亡率相关,难治性腹水者亦然。
- 49%患者停药,驱动因素为低平均动脉压、感染和急性肾损伤,停药未与更高死亡率相关。
- 40%患者出院前重启β受体阻滞剂,主要驱动因素为平均动脉压升高。
核心结论
- 在低平均动脉压时停用β受体阻滞剂、待平均动脉压回升后重启的前提下,β受体阻滞剂在肝硬化腹水患者(包括难治性腹水患者)中使用是安全的。
- 研究提示β受体阻滞剂可能具有抗炎有益作用。
研究设计与样本
- NACSELD(北美终末期肝病研究联盟)数据库的子分析,该数据库包含肝硬化住院患者的前瞻性数据。
- 数据来自7个中心,纳入腹水患者超过100例。
- β受体阻滞剂停药与重启数据通过病历回顾收集。
- 共716例患者,307例(43%)入院时使用β受体阻滞剂,366例(51%)为难治性腹水,随访至死亡或出院。
主要发现
- β受体阻滞剂使用与入院时较低的白细胞计数相关。
- 肝硬化腹水住院患者使用β受体阻滞剂未与更高死亡率相关,难治性腹水患者中亦然。
- 各组间平均动脉压(MAP)未见显著变化。
- 49%的患者停用β受体阻滞剂,停药时低MAP、感染和急性肾损伤是驱动因素,但停药未与更高死亡率相关。
- 40%的患者在出院前重启β受体阻滞剂,主要驱动因素为MAP升高。
临床怎么用
- 作者认为,在肝硬化腹水患者(包括难治性腹水)中使用β受体阻滞剂是安全的,前提是在低MAP时停药、MAP回升后重启。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It has been suggested that beta-blockers may increase mortality in patients with cirrhosis and refractory ascites but the effect of beta-blockers discontinuation or reinitiation has not been examined. AIMS: To compare, in hospitalised patients with cirrhosis and ascites, the effect of BB on survival and to examine the effect/predictors of beta-blockers discontinuation and reinitiation. METHODS: Sub-analysis of NACSELD (North American consortium for the study of end-stage liver disease, database containing prospective data on hospitalised patients with cirrhosis) data from 7 centres enrolling >100 patients with ascites. Data on BB discontinuation and reinitiation were collected by chart review. RESULTS: Seven hundred and sixteen patients, 307 (43%) on beta-blockers at admission and 366 (51%) with refractory ascites, were followed to death or hospital discharge. Beta-blocker use was associated with a lower white blood cell count at admission. Beta-blocker use in hospitalised patients with ascites was not associated with a higher mortality, even in those with refractory ascites. No significant changes in mean arterial pressure (MAP) were observed between groups. Discontinuation of beta-blockers (49%) was driven by low MAP, infection and acute kidney injury at time of discontinuation but was not associated with a higher mortality. Beta-blocker reinitiation occurred in 40% prior to discharge and was mainly driven by an increase in MAP. CONCLUSIONS: Beta-blocker use is safe in patients with cirrhosis and ascites (including those with refractory ascites) provided beta-blockers are discontinued in the presence of a low MAP and reinitiated once MAP reincreases. A potentially beneficial anti-inflammatory effect of beta-blockers is suggested.
引用
- Bhutta AQ, Garcia-Tsao G, Reddy KR, et al. Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. Aliment Pharmacol Ther. 2017. PMID: 28994122. doi:10.1111/apt.14366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。